Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Scythian Biosciences Corp. Retains Hybrid Financial Ltd. for Investor Relations Activities


Posted on: 17 Aug 17

TORONTO, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the “Company”) (TSXV:SCYB) announces that it has retained the services of Hybrid Financial Ltd. (”Hybrid Financial”) for strategic investor relations activities. The initiatives includes marketing and investor relations services for the Company.

Pursuant to the agreement Hybrid Financial will receive a monthly fee of $15,000. The agreement commenced August 1, 2017, for an initial term of three months, following which the agreement may be renewed by the Company on a month-to-month basis. The Company will pay the monthly fee from its cash on hand. The agreement is subject to the approval of the TSX Venture Exchange.

About Scythian Biosciences Corp.

Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination. 

Scythian’s mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen.  The University of Miami believes that Scythian’s scientific approach shows significant promise and differs from previous approaches to treat this growing problem.  The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian’s clinical studies to be undertaken at their world-class facilities.   

Gillian A. Hotz, PhD, is leading Scythian’s program at the University of Miami.  Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation.  She has extensive experience in neurocognitive testing.  Dr. Hotz has been the co-director of University of Miami Miller School of Medicine’s Concussion Program since 1995. 

Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.

CONTACT: Contact Information For further information, please contact: Scythian Biosciences Corp. Jonathan Gilbert, CEO Phone: (212) 729-9208 Email: info@scythianbio.comGlobeNewswire
globenewswire.com

Last updated on: 21/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.